12 Health Care Stocks Moving In Monday's Pre-Market Session
Atara Biotherapeutics Inc ATRA | 4.71 | -3.20% |
Aura Biosciences Inc AURA | 6.60 | -1.20% |
Cuprina Holdings (Cayman) Limited Class A CUPR | 0.52 | +31.49% |
CEL-SCI Corporation CVM | 4.29 | -0.69% |
Dianthus Therapeutics, Inc. DNTH | 84.59 | -1.06% |
Gainers
- Relmada Therapeutics (NASDAQ:RLMD) stock rose 48.3% to $6.6 during Monday's pre-market session. The market value of their outstanding shares is at $326.3 million.
- Hims & Hers Health (NYSE:HIMS) shares rose 44.09% to $22.68. The market value of their outstanding shares is at $3.5 billion.
- Xenon Pharmaceuticals (NASDAQ:XENE) stock moved upwards by 42.48% to $59.76. The market value of their outstanding shares is at $3.2 billion.
- uniQure (NASDAQ:QURE) shares increased by 36.58% to $19.49. The market value of their outstanding shares is at $888.9 million.
- Dianthus Therapeutics (NASDAQ:DNTH) shares moved upwards by 24.23% to $81.0. The company's market cap stands at $2.8 billion. As per the press release, Q4 earnings came out today.
- Atara Biotherapeutics (NASDAQ:ATRA) shares moved upwards by 22.24% to $6.32. The company's market cap stands at $37.2 million.
Losers
- Olema Pharmaceuticals (NASDAQ:OLMA) shares decreased by 42.6% to $12.36 during Monday's pre-market session. The company's market cap stands at $1.7 billion.
- Zymeworks (NASDAQ:ZYME) stock declined by 33.1% to $16.11. The company's market cap stands at $1.8 billion.
- ProQR Therapeutics (NASDAQ:PRQR) stock declined by 15.74% to $1.5. The company's market cap stands at $188.5 million.
- Cuprina Holdings (Cayman) (NASDAQ:CUPR) stock fell 15.08% to $0.33. The market value of their outstanding shares is at $2.8 million.
- Aura Biosciences (NASDAQ:AURA) shares declined by 11.43% to $4.96. The company's market cap stands at $355.6 million.
- CEL-SCI (AMEX:CVM) stock fell 10.92% to $3.51. The market value of their outstanding shares is at $27.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
